液体活检在治疗反应和耐药性预测中的生物标志物研究进展。

Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.

机构信息

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, University of Manchester, Oxford Road, Manchester M13 9PL, UK.

出版信息

Cancer Cell. 2020 Apr 13;37(4):485-495. doi: 10.1016/j.ccell.2020.03.012.

DOI:10.1016/j.ccell.2020.03.012

PMID:32289272

Abstract

Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations within an individual's tumor. Patients' responses to targeted therapies are commonly followed by treatment resistance. Here, we survey liquid biopsies as alternatives to tumor biopsies to assess predictive and therapy response biomarkers. We examine the potential of liquid biopsies to meet the challenges of minimal residual disease monitoring after curative intent treatment for earlier detection of disease recurrence. We focus on blood, the most commonly collected minimally invasive clinical sample, and on the two most widely studied assays, circulating tumor DNA and circulating tumor cells.

摘要

预测生物标志物有助于选择针对个体肿瘤内分子改变的个体化治疗。患者对靶向治疗的反应通常会导致治疗耐药。在这里，我们调查液体活检作为肿瘤活检的替代方法，以评估预测和治疗反应生物标志物。我们研究了液体活检在满足最小残留疾病监测治疗后早期发现疾病复发的挑战方面的潜力。我们专注于血液，这是最常采集的微创临床样本，以及两种研究最广泛的检测方法，循环肿瘤 DNA 和循环肿瘤细胞。